Sökning: "Affibody molecules"
Visar resultat 31 - 35 av 61 avhandlingar innehållade orden Affibody molecules.
31. Affinity protein based inhibition of cancer related signaling pathways
Sammanfattning : Dysregulation of protein activity, caused by alterations in protein sequence, expression, or localization, is associated with numerous diseases. In order to control the activity of harmful protein entities, affinity ligands such as proteins, oligonucleotides or small molecules can be engineered to specifically interact with them to modulate their function. LÄS MER
32. Chemical Engineering of Small Affinity Proteins
Sammanfattning : Small robust affinity proteins have shown great potential for use in therapy, in vivo diagnostics, and various biotechnological applications. However, the affinity proteins often need to be modified or functionalized to be successful in many of these applications. LÄS MER
33. Engineering of alternative scaffold derived drug conjugates and fusion-toxins for targeted cancer therapy
Sammanfattning : Cancer is a major health problem, with premature death for many patients, and with a high monetary cost to society. The disease is complex to treat due to the many different types, but also because the disease-causing cells, that needs to be removed, are very similar to the normal cells. LÄS MER
34. Bacterial display systems for engineering of affinity proteins
Sammanfattning : Directed evolution is a powerful method for engineering of specific affinity proteins such as antibodies and alternative scaffold proteins. For selections from combinatorial protein libraries, robust and high-throughput selection platforms are needed. LÄS MER
35. Rational and combinatorial protein engineering for vaccine delivery and drug targeting
Sammanfattning : This thesis describes recombinant proteins that have been generated by rational and combinatorial protein engineering strategies for use in subunit vaccine delivery and tumor targeting.In a first series of studies, recombinant methods for incorporating immunogens into an adjuvant formulation, e.g. LÄS MER